Inhibrx sees positive Ox40 signs | ApexOnco - Clinical Trials news and analysis

Inhibrx reported encouraging phase 2 data for INBRX-106 in first-line head and neck cancer, with ORR of 44% for the Keytruda combination versus 21% for Keytruda alone and 23% in Keynote-048. Safety was described as predominantly low-grade with no treatment-related deaths, and the company plans to begin the phase 3 portion of Hexagon next quarter. Shares rose 6% as investors reacted to the better-than-comparator efficacy signal in an unloved Ox40 agonism mechanism.

Analysis

This read-through is less about one asset and more about a sentiment inflection in an abandoned mechanism: if a previously disfavored immune-stimulation angle can still generate clean separation in a randomized setting, the market will briefly re-rate the whole basket of “dead” oncology platforms. The second-order winner is not just the sponsor but any company with differentiated checkpoint-combination exposure, because the bar for mechanism viability just moved from theoretical to clinically de-risked, at least enough to reopen partnering discussions.

For PFE and ABBV, the implication is asymmetric but not immediate. They are not directly exposed operationally, but they are exposed reputationally and strategically: renewed enthusiasm for this class raises the odds that rivals restart programs they abandoned, which can siphon capital and BD attention away from franchises these firms would otherwise dominate in IO combination workflows. The real competitive pressure is on large-cap pharma’s “internal kill-rate” discipline — if the signal holds into progression endpoints, the opportunity cost of having exited early becomes visible to investors and may force a more expensive re-entry via dealmaking rather than internal development.

The catalyst stack is binary over the next 6-9 months: progression data will matter much more than response rate, and the next leg up depends on whether the effect persists enough to shift the hazard curve rather than just the waterfall. If the readout compresses toward durability, the stock can stay bid and attract optionality from strategics; if PFS stalls, the current rally likely fades quickly because investors will reclassify this as a biologic activity signal without line-of-sight to registrational value. The biggest risk is that the early enthusiasm is front-running big pharma interest that never actually materializes unless the phase 3 design can credibly beat an already established benchmark.

Contrarian take: the move may be modestly underdone in the name itself but overdone for the broader mechanism. A 6% equity reaction implies some probability of platform resurrection, yet the right framing is that this is a financing and partnering event first, not a de-risked commercial thesis. The tradeable edge is to own the idiosyncratic beneficiary while fading any read-across to incumbent IO leaders that may face only indirect, delayed competitive pressure.

Key Decisions for Investors

• Long INBRX into the next PFS catalyst window over the next 3-6 months; use size discipline because the setup is high-beta and binary, but the upside extends materially if durability confirms the response signal.
• For a relative-value expression, short PFE and ABBV as a light pair against a basket of emerging IO platforms for 1-3 months; thesis is not direct earnings risk but incremental BD/strategic pressure if the mechanism stays alive.
• If you want lower-risk convexity, buy INBRX call spreads dated through the Q4 PFS readout; this captures the partnering/re-rating tail while limiting downside if durability disappoints.
• Avoid chasing large-cap checkpoint names on this headline alone; any read-through to incumbent pharma is a 6-18 month strategic issue, not a near-term P&L driver.